SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
959Harry, Do you have in-vitro and in-vivo data for 34060 affinity to different GAMiljenko Zuanic-6/26/2002
958<<Dr. Tracy, Wouldn't a short-acting anxiolytic find a market for a sNeuroInvestment-6/26/2002
957Dr. Tracy, Wouldn't a short-acting anxiolytic find a market for a short-durkeokalani'nui-6/26/2002
956short interest soars to 2,989,021. (eom)scaram(o)uche-6/26/2002
9551) I sincerely hope that 34060 is not a mild anxiolytic, or at least, not a clinNeuroInvestment-6/26/2002
954Thanks! (eom)scaram(o)uche-6/25/2002
953I agree with Jim and Wilder. Why give up development cost and risk reduction milMiljenko Zuanic-6/25/2002
952PFE or MRK, Worldwide, less Japan. 40% royalty on sales; they pay to register ikeokalani'nui-6/25/2002
951$100M upfront, $200M milestones, 50/50 with pfizer, ahp, glx or mrk. Or $200Mrkrw-6/25/2002
950OK, so.... now we're going to have a lull. MZ, what sort of milestones (Gscaram(o)uche-6/25/2002
949Tuesday June 25, 6:01 am Eastern Time Press Release SOURCE: Neurocrine Biosciencsmh-6/25/2002
948Monday June 24, 6:00 am Eastern Time Press Release SOURCE: Neurocrine BioscienceMiljenko Zuanic-6/24/2002
947RESEARCH ALERT-Morgan Stanley starts Neurocrine NEW YORK, June 18 (Reuters) - mopgcw-6/18/2002
946<i>Paradoxically, American Cyanamid makes another popular insomnia drug, SDoc Bones-6/18/2002
945Another Drug to Fight Insomnia By SABRA CHARTRAND nytimes.com EARLY this monthmichael_f_murphy-6/17/2002
944Neurocrine Biosciences Reports Additional Phase I/II Safety Results With NBI-602scaram(o)uche-6/14/2002
943jpet.aspetjournals.org Vol. 302, Issue 1, 145-152, July 2002 Pharmacological EMiljenko Zuanic-6/13/2002
942DOVP, with two candidates in clinic is interesting play, even without royalty frMiljenko Zuanic-6/13/2002
941Cool thought. I like the diversity of projects at NBIX. You did say "nearscaram(o)uche-6/13/2002
940Considering that DOVP is trading at a huge (40%?) discount to cash, and that thetuck-6/13/2002
939>SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Ntuck-6/12/2002
938Tuesday June 4, 6:01 am Eastern Time Press Release SOURCE: Neurocrine Biosciencesmh-6/4/2002
937Tuesday June 4, 6:05 am Eastern Time Press Release SOURCE: Neurocrine Biosciencescaram(o)uche-6/4/2002
936Thank you. And thank you for reminder on MR formulation. Did not know patent keokalani'nui-5/14/2002
935Wilder, <<If I am right that the company would have received a notice of Miljenko Zuanic-5/14/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News